B Vitamins and Hearing — Body Handbook

სმენა · §41

B Vitamins and Hearing

The inner ear runs on the smallest blood vessels in your body, and they don't tolerate sloppy vitamin status well. In adults past 60, in long-term vegans, and in anyone who's been on metformin or acid-blocking drugs for years, low B12 or folate quietly raises a blood marker called homocysteine — which damages the tiny vessels feeding the inner ear and accelerates hearing decline. Correcting a real deficiency can quiet ringing in the ears and slow further loss; taking the same pill when your levels are fine does almost nothing. Who should test, what the numbers mean, and what the trial evidence actually supports — below.

შეამოწმე · საჭიროებისამებრ მტკიცებულება განვითარებადი თავი სმენა

The payoff lands narrowly. If you're in one of the at-risk groups and you're actually deficient, fixing it can ease the ringing, lift the energy floor, and prevent slower-burn nerve damage that goes well beyond hearing. Everyone else gets little — a B-complex isn't a hearing supplement. The whole intervention is about $30–100 for a one-time blood test and $20 a year for a pill. Practically free for the people it helps.

The cochlea — the spiral shell in your inner ear that turns sound into nerve signals — is fed by one of the smallest, most isolated arteries in the body. No backup vessels, no second route. Whatever harms the cells lining those vessels harms hearing.

That's where B₁₂ and folate come in. Both vitamins are needed to clear homocysteine, an amino acid your cells produce as routine metabolic waste. Run low on either and homocysteine accumulates in the blood. High homocysteine corrodes the lining of small vessels and triggers oxidative stress inside cells — bad news for the delicate hair cells in the cochlea, which depend on a steady blood supply and a tight chemical balance to do their job Martinez-Vega et al. 2017.

There's a second thread on top of the vascular story: B₁₂ is also required to maintain the myelin sheath that insulates nerves, including the cochlear nerve carrying signals from ear to brain. A long-running B₁₂ shortage doesn't just starve the blood vessels — it slowly degrades the wiring itself.

What the human studies actually show

Strong observational signal, modest trial signal, sharp population dependence. That's the honest summary.

The cross-sectional studies stack up. In 55 healthy women aged 60 to 71, those with hearing loss had B₁₂ levels roughly 38% lower than women hearing normally — and 48% lower if they weren't taking a supplement Houston et al. 1999. In 126 Nigerian elders, low serum folate tracked closely with worse high-frequency hearing Lasisi et al. 2010. The Australian Blue Mountains study, which followed nearly 3,000 adults over 50, found people with high homocysteine had 64% higher odds of hearing loss, and low folate raised the odds of mild loss by 37% Gopinath et al. 2010. The pattern repeats across continents, age groups, and lab methods — which is the kind of consistency that makes you take an association seriously.

The one randomized trial moved the needle, but barely. Older Dutch adults with elevated homocysteine took 800 micrograms of folic acid daily — or placebo — for three years.

For tinnitus specifically, the trial signal is cleaner — but narrower. A small randomized study gave weekly B₁₂ injections to people with chronic ringing in the ears. Severity scores dropped, but only in the people who turned out to be B₁₂-deficient at the start. Non-deficient patients got no benefit; placebo patients got no benefit Singh et al. 2016. An earlier Israeli study found nearly half of military personnel with noise-induced hearing loss and tinnitus were B₁₂-deficient, versus 19% of those with normal hearing Shemesh et al. 1993. The takeaway, repeated across the tinnitus literature: B₁₂ helps the people who need B₁₂. It doesn't help anyone else.

A 2025 review pooling nine studies on B₁₂ and hearing reached the same shape of conclusion — lower B₁₂ consistently associates with worse hearing, especially above 4 kHz, but heterogeneity in cutoffs and confounders means no one has nailed down a single number that means "treat" Rodrigues et al. 2025.

Who actually needs to think about this

The whole entry is about a few populations where deficiency is common enough to be worth catching, not a general recommendation. If you're not in one of these groups and you eat a normal mixed diet, you can stop reading. For everyone else:

Adults over 60. The stomach lining thins with age — a condition called atrophic gastritis that affects 20 to 30 percent of people past 60 — and that thinning slows B₁₂ release from food. Outright B₁₂ deficiency runs between 5 and 40 percent in older adults depending on the cutoff used. It's the single biggest risk group NIH ODS Vitamin B₁₂ 2024.
Vegans and strict vegetarians. B₁₂ exists naturally only in animal foods. Without a supplement or fortified plant milk, B₁₂ deficiency rates in long-term vegans exceed 60 percent. The fix is built into the diet's reality — a daily pill — but plenty of people skip it.
Long-term metformin users. The world's most-prescribed diabetes drug interferes with B₁₂ absorption in the small intestine. Between 10 and 30 percent of people on metformin become B₁₂-deficient; with high doses over many years, the number can reach 50 percent. The UK regulator now classes B₁₂ deficiency as a common side effect of metformin and recommends monitoring people on it MHRA 2022.
Long-term users of acid-blocking drugs. Proton-pump inhibitors (omeprazole, pantoprazole, esomeprazole) and H₂-blockers (famotidine, ranitidine) suppress stomach acid, which is needed to release B₁₂ from food. After a year or more, deficiency rates climb meaningfully.
Pernicious anemia or prior stomach surgery. An autoimmune attack on the stomach cells that make intrinsic factor — or surgical removal of those cells — blocks B₁₂ absorption entirely. People in this group will need lifelong injections or high-dose oral B₁₂.
Noisy workplaces. If you're regularly exposed to loud machinery, gunfire, or live music, B₁₂ status is one of the few modifiable factors on top of the obvious step of wearing ear protection. Israeli soldiers with both noise-induced hearing loss and tinnitus were nearly 2.5 times as likely to be B₁₂-deficient as those with normal hearing Shemesh et al. 1993.

How to test, and what to do with the result

Ask your doctor for two blood tests: serum B₁₂ and serum folate. If you're on metformin or a proton-pump inhibitor and your last B₁₂ was anywhere in the gray zone, also ask for methylmalonic acid (MMA) — it's the more sensitive marker and picks up functional deficiency that a basic B₁₂ number misses.

The standard lab cutoff for B₁₂ deficiency is 200 pg/mL (148 pmol/L). Between 200 and 300 pg/mL is the gray zone — not formally deficient, but enough people in this range have neurological symptoms that many geriatricians treat anyway, especially over 60. Below 200, treat. For folate, below 11 nmol/L is the threshold linked to hearing-loss associations in the big cohort studies Gopinath et al. 2010 NIH ODS Vitamin B₁₂ 2024.

What the marketing gets wrong

"B₁₂ for tinnitus" is a product category on Amazon. The science underneath that category is narrower than the labels suggest. B₁₂ reliably eases tinnitus in people who are B₁₂-deficient. In the rest, the trial data don't show a benefit. The Singh pilot was clean on this — only the deficient half of the group improved, even at high injection doses Singh et al. 2016. Spending money on B-complex pills when your levels are already fine is buying expensive urine.

The second common claim — that folic acid slows age-related hearing loss — comes from one trial in a country without folic-acid food fortification, and the effect was 0.7 dB over three years. The US has fortified flour, rice, and most cereals since 1998. Most American adults already get plenty of folate from the food supply, and the trial's conditions don't apply Durga et al. 2007 Kabagambe et al. 2018.

The third misconception is the most painful to deliver: vitamins won't restore the high-frequency hearing you've already lost. The hair cells that pick up consonants and birdsong don't regrow. What B₁₂ and folate can plausibly do is slow further loss and address the reversible piece — the nerve and vascular contributions in deficient people. They aren't a rewind button.

What happens if you keep ignoring it

The hearing piece is the small end of the stake. The big end is that a B₁₂ deficiency you leave alone for years stops being reversible. Nerves in the legs go numb in patches. Balance gets worse. The version of you who used to remember names starts asking your partner who that person at the wedding was, again. Once the spinal cord and brain damage is established, taking the pill no longer brings it back.

In the auditory dimension specifically, untreated low folate or B₁₂ in your 60s shows up later as conversations you can't follow at restaurants, asking your grandkids to repeat themselves, turning the TV up while your partner asks you to turn it down. The Blue Mountains data put a number on this: high homocysteine in older adults raised the odds of measurable hearing loss by roughly two-thirds Gopinath et al. 2010. The version of that decade where someone catches the deficiency at a routine appointment looks different from the version where nobody does.

The second-order stake is dementia. Untreated hearing loss is now one of the largest modifiable risk factors for it — partly through social withdrawal, partly through the cognitive cost of constant listening effort. And B₁₂ deficiency causes its own slow cognitive decline on top of that, separately from the ear. The two pile on each other. The dinner party you stop going to because you can't follow the conversation is the same dinner party you'd stop going to anyway as the cognitive piece worsens.

What changes when you actually fix it

For someone with a genuine deficiency, the timeline runs roughly like this. Weeks one and two: not much yet — the body is restocking. Weeks three and four: the energy floor lifts. The afternoon fade that you'd blamed on aging doesn't show up the same way. By week six, the tingling in fingers and toes — if you had it — starts retreating. People with tinnitus tied to deficiency notice the volume of the ringing easing, sometimes substantially; the trial data show measurable improvement on tinnitus severity scores by six weeks of treatment Singh et al. 2016.

Months three to six: cognitive complaints — the word-retrieval gap, the brain fog — settle. The low-grade mood drag that often shadows long-running B₁₂ deficiency tends to ease too; people with documented deficiency score better on depression and anxiety measures once their levels are restored, though the effect is modest and inseparable from the lift in energy and cognition. Your partner stops asking if something's wrong. The hearing piece is the slowest. You're not going to notice the ear changes day by day; you'll notice them by their absence — the conversation in the loud restaurant that doesn't exhaust you the way it would have, the meeting where you didn't have to ask your colleague to repeat the question.

Year one and beyond: the realistic payoff isn't restored hearing. It's a slower slope on what you'd otherwise lose. The Dutch folic-acid trial showed roughly a 40 percent reduction in the rate of speech-frequency hearing decline over three years in the supplemented group Durga et al. 2007. That doesn't feel like anything in a single year. Across a decade, it's the difference between needing hearing aids at 72 and at 78.

If you're not deficient and not in a risk group, the payoff for taking the same pill is roughly zero. That's the most honest framing.

The common ways this goes wrong

Treating B₁₂ like a generic hearing supplement. A 70-year-old buys B-complex pills, takes them for a year, hears nothing different, concludes "vitamins don't work for hearing." Their B₁₂ level was 540 pg/mL the whole time. The pills weren't broken — the deficiency was never there Singh et al. 2016.
Stopping at one borderline test. Serum B₁₂ comes back at 220 pg/mL. The doctor calls it "normal" and moves on. The patient is in the gray zone where MMA testing would actually answer the question, and where many people with this number turn out to be functionally deficient. Ask for the follow-up test.
Loading up on folic acid before checking B₁₂. High-dose folate masks the blood-count signal of a B₁₂ shortage. The standard lab work looks fine while nerve damage progresses. Test B₁₂ first.
Treating once, then quitting. If you're on metformin or a PPI, or you're vegan, the cause of the deficiency isn't going anywhere. Stopping the supplement after the labs normalize means the deficiency returns. The pill is daily, indefinitely.
Expecting a rewind. Once high-frequency hearing is gone, it doesn't come back. The realistic goal is slowing further loss and addressing the reversible piece — fatigue, tinnitus, neurological symptoms — not restoring what's already lost.

1. Substance + claimed effects

The substance is vitamin B₁₂ (cobalamin) and folate (vitamin B₉) status, considered specifically through the lens of auditory function — cochlear circulation, age-related hearing decline (presbycusis), and chronic subjective tinnitus. Both vitamins are required co-substrates in one-carbon metabolism: deficiency in either drives elevation of plasma total homocysteine (tHcy), and hyperhomocysteinemia is the most credible mechanistic bridge between B-vitamin status and cochlear injury Martinez-Vega et al. 2017. The claims this entry assesses: (a) deficient or low-normal B₁₂ and/or folate status is associated with worse hearing thresholds in older adults; (b) the association is mediated principally by reduced cochlear blood flow plus direct homocysteine-induced oxidative damage to inner-ear structures; (c) supplementation with folic acid can modestly slow the speech-frequency decline of presbycusis in a population without folic-acid food fortification; (d) tinnitus severity improves with B₁₂ repletion only in patients with documented deficiency; (e) high-risk groups — adults 60+, vegans/strict vegetarians, long-term metformin or proton-pump-inhibitor users, those with atrophic gastritis or pernicious anemia — warrant proactive testing.

2. Evidence by addressing question

2a. mechanism

Science / mechanism. B₁₂ and folate are the co-factors for methionine synthase, which remethylates homocysteine to methionine. When either is deficient, homocysteine accumulates in plasma and tissues. Elevated tHcy damages vascular endothelium through several pathways (reduced NO bioavailability, oxidative stress, inflammation) and the cochlea — supplied by the labyrinthine artery, an end-arterial branch of the basilar system with no collateral circulation — is uniquely vulnerable to microvascular insults Martinez-Vega et al. 2017. The stria vascularis, which generates the endocochlear potential required for hair-cell mechanotransduction, depends on intact capillary perfusion; even modest reductions in flow can collapse the K⁺ gradient that drives sound transduction.

Beyond the vascular story, animal data implicate direct homocysteine toxicity in the cochlea. C57BL/6J mice placed on a folate-deficient diet for 8 weeks show a 7-fold drop in serum folate and a 3-fold rise in tHcy, accelerated hearing loss measured by auditory brainstem responses, increased TUNEL-positive apoptotic cochlear cells, and elevated protein N-homocysteinylation in cochlear extracts — a post-translational modification that inactivates and aggregates proteins Martinez-Vega et al. 2015. CBA/Ca mice on long-term folate-deficient diets show accelerated progressive hearing loss, supporting the effect in a strain not predisposed to early presbycusis. Hyperhomocysteinemia also disrupts cochlear gap junction proteins (connexins Cx30/Cx43), which are essential for K⁺ recycling within the organ of Corti Martinez-Vega et al. 2017.

For tinnitus, the proposed mechanism extends from the same vascular logic — destruction of stria vascularis microvasculature lowers endocochlear potential and is hypothesized to generate the aberrant spontaneous neural activity perceived as tinnitus Shemesh et al. 1993. Cobalamin's role as a co-factor in myelin maintenance is the secondary mechanistic thread: B₁₂ deficiency demyelinates peripheral and central neurons, and the cochlear nerve and brainstem auditory pathways are not exempt Singh et al. 2016.

2b. evidence

Cross-sectional observational data. Houston et al. evaluated 55 healthy women aged 60–71 with comprehensive audiometry: serum B₁₂ was 38% lower in women with hearing impairment than in those with normal hearing, and 48% lower among those not taking B₁₂ supplements Houston et al. 1999. Lasisi et al. studied 126 Nigerian elderly (>60 y); serum folate averaged 412 nmol/L in normal-hearing subjects versus 279 nmol/L in those with speech-frequency hearing loss, and both folate and B₁₂ correlated negatively with high-frequency thresholds — though after age adjustment, only folate remained significant Lasisi et al. 2010.

The Blue Mountains Hearing Study (n=2956, ≥50 y) showed elevated tHcy (>20 µmol/L) associated with a 64% increase in odds of prevalent hearing loss (OR 1.64, 95% CI 1.06–2.53), and low serum folate (<11 nmol/L) raising odds of mild hearing loss (OR 1.37, 95% CI 1.04–1.81). Serum B₁₂ was not independently associated, and no temporal link was observed for incident loss — leaving open whether the association is causal or reflects shared aging confounders Gopinath et al. 2010.

The NHANES 2003–2004 analysis (n=1149, ages 20–69) is the largest US-based dataset addressing this question post-folic-acid-fortification. The authors found a U-shaped association between erythrocyte folate and hearing loss: moderate erythrocyte folate (582–741 nmol/L) was associated with roughly 30% lower odds of hearing loss versus the lowest quartile, with no benefit at the highest quartile. Once folate status was accounted for, B₁₂ was not independently associated with hearing in this US population — likely reflecting the relative scarcity of frank B₁₂ deficiency in a working-age US sample Kabagambe et al. 2018. A relevant null: Berner et al. found no association between B₁₂/folate and hearing thresholds in 91 elderly Danes (median 78 y), though the homocysteine analysis was not the primary endpoint Berner et al. 2000.

Randomized trial. Durga et al. ran the only large RCT on this question to date: 728 Dutch adults aged 50–70 with elevated tHcy (≥13 µmol/L) and normal B₁₂ received 800 µg folic acid or placebo daily for 3 years. The folic-acid arm gained 1.0 dB in low-frequency thresholds (0.5/1/2 kHz) versus 1.7 dB in placebo — a between-group difference of −0.7 dB (95% CI −1.2 to −0.1, P=0.020). The high frequencies (4/6/8 kHz) showed no benefit Durga et al. 2007. The trial was conducted in a country without folic-acid food fortification; baseline folate was about half of US norms. Whether the effect would replicate in a fortified population remains untested.

Tinnitus. Shemesh et al. found 47% of Israeli military personnel with chronic tinnitus + noise-induced hearing loss were B₁₂-deficient (≤250 pg/mL) versus 27% with hearing loss alone and 19% with normal hearing (p<0.023). Twelve patients reported subjective improvement after parenteral B₁₂ replacement Shemesh et al. 1993. Singh et al. conducted a randomized, double-blind pilot study (n=40) of weekly IM methylcobalamin 2500 µg × 6 weeks versus placebo: 42.5% of tinnitus patients were B₁₂-deficient, and tinnitus severity scores improved only in deficient patients on B₁₂ — no improvement in non-deficient patients or placebo recipients Singh et al. 2016.

Systematic review. A 2025 systematic literature review pooled nine studies of B₁₂ status and hearing thresholds. Most found statistically significant associations between lower B₁₂ and worse thresholds, particularly at ≥4 kHz; the review concluded B₁₂ deficiency coupled with elevated tHcy and low folate contributes to hearing loss in the elderly, but flagged heterogeneity in study designs, deficiency cutoffs, and confounding control Rodrigues et al. 2025.

2c. protocol

Testing. Serum B₁₂ below 200 pg/mL (148 pmol/L) is the most common deficiency cutoff; 200–300 pg/mL is the low-normal range where deficiency is plausible and confirmatory testing with methylmalonic acid (MMA) or homocysteine is indicated NIH ODS Vitamin B₁₂ 2024. MMA is the more sensitive marker — elevated MMA confirms functional B₁₂ deficiency even when serum B₁₂ is in the gray zone. In older adults specifically, some practitioners use a higher functional threshold (~300–350 pg/mL) given the dossier of associations with cognitive and neurological symptoms above the standard deficiency cutoff. Serum folate (or erythrocyte folate for longer-term status) is the parallel test; folate <11 nmol/L correlates with hearing-loss associations in the Blue Mountains data Gopinath et al. 2010.

Repletion. The RDA for B₁₂ is 2.4 µg/day; for folate, 400 µg/day DFE NIH ODS Vitamin B₁₂ 2024 NIH ODS Folate 2024. For confirmed B₁₂ deficiency, oral 1000–2000 µg cyanocobalamin or methylcobalamin daily for 1–3 months is as effective as IM 1 mg weekly × 8 weeks for non-malabsorptive etiologies; passive intestinal absorption (~1% of dose) bypasses the intrinsic-factor pathway. Folic-acid supplementation at 400–800 µg/day matches the Durga protocol; doses above 1000 µg/day approach the tolerable upper intake limit and can mask B₁₂ deficiency on a CBC by correcting the macrocytic anemia while neurological progression continues NIH ODS Folate 2024. Form (cyano- vs methyl-) does not appear clinically decisive at adequate doses; adherence matters more.

2d. contraindications

The folate-masking-B₁₂ problem. The salient hazard is high-dose folic acid (≥1 mg/day) given without B₁₂ status known: folate corrects the macrocytic anemia of B₁₂ deficiency, removing the CBC signal that triggers further workup, while subacute combined degeneration of the spinal cord progresses unchecked NIH ODS Folate 2024. The UL for folic acid from supplements/fortified food is 1000 µg/day for this reason.

Beyond that, both vitamins have unusually clean safety profiles. B₁₂ has no established tolerable upper intake limit; the only documented adverse effects at very high doses are rare cutaneous reactions to cyanocobalamin NIH ODS Vitamin B₁₂ 2024. There are no hearing-specific contraindications.

2e. misconceptions

The widely circulated claim — popularized by some supplement marketers and tinnitus-influencer content — is that B₁₂ reliably treats tinnitus. The trial data are clear: B₁₂ reduces tinnitus severity only in patients with documented B₁₂ deficiency. In non-deficient patients, results are null Singh et al. 2016. The Karli 2013 study of 100 tinnitus patients (PubMed 23909117) reported some improvement in B₁₂-deficient patients but no statistically significant benefit overall in tinnitus from B₁₂ replacement, consistent with the "fixes-deficiency-not-tinnitus" pattern. A second misconception: that high-dose folate or B-complex supplementation will slow hearing loss in already-replete adults. The Durga trial selected for elevated homocysteine and was conducted in a non-fortified population; its 0.7 dB benefit over 3 years is not transferable to a US adult eating fortified cereal with adequate baseline status Durga et al. 2007.

2f. audience

Risk concentrates sharply by population:

Adults ≥60. Atrophic gastritis affects 20–30% of those ≥60 and impairs food-cobalamin release. B₁₂ deficiency runs 5–40% depending on cutoff; pernicious anemia prevalence is ~1.9% at 60+ vs 0.1% in the general population. Folate absorption also declines with age.
Vegans and strict vegetarians. Animal products are the only natural dietary B₁₂ source. B₁₂ deficiency prevalence exceeds 60% in vegans without supplementation. This is the most fixable population — a $20/year supplement closes the gap.
Long-term metformin users. 10–30% develop B₁₂ deficiency on long-term metformin via altered ileal absorption; up to 50% with prolonged high-dose use. The UK MHRA issued explicit guidance in 2022 designating B₁₂ deficiency a common adverse effect of metformin and recommending monitoring in symptomatic patients MHRA 2022.
Long-term PPI / H₂-blocker users. Hypochlorhydria from acid suppression impairs cobalamin release from food protein; observational data show meaningfully increased deficiency rates after >1 year of therapy.
Pernicious anemia / autoimmune gastritis. Autoimmune destruction of parietal cells abolishes intrinsic factor production, blocking active B₁₂ absorption.
Noise-exposed populations. Shemesh's military cohort suggests B₁₂-deficient individuals exposed to noise are at higher risk of tinnitus and NIHL than B₁₂-replete peers Shemesh et al. 1993.

2g. failure-modes

The most common failure pattern is treating B₁₂/folate as a generic hearing-loss remedy: a non-deficient 70-year-old with high-frequency presbycusis takes a B-complex for a year, hears no improvement, and concludes "vitamins don't work." The trial data don't support a hearing benefit in replete adults; they support correction of deficiency in deficient patients Singh et al. 2016 Kabagambe et al. 2018. A second failure: testing once, finding 220 pg/mL, and stopping — without MMA confirmation in the gray zone. A third: high-dose folic acid added before B₁₂ status is documented, then neurological deficits emerge while the CBC looks normal. A fourth: expecting reversal of established high-frequency presbycusis — the cochlear hair-cell damage is not reversible by repleting vitamins; the realistic goal is slowing further decline and addressing reversible neural/vascular contributions.

2h. stakes

Untreated B₁₂ deficiency causes irreversible neurological damage on a timescale of months to years — peripheral neuropathy, subacute combined degeneration of the spinal cord, cognitive decline, dementia. The hearing-specific stakes layer onto a broader pattern of preventable disability. In the auditory dimension specifically, the cumulative effect is twofold: (a) faster slope of age-related hearing decline in populations with low folate/elevated tHcy Gopinath et al. 2010 Durga et al. 2007; (b) higher risk of chronic tinnitus in B₁₂-deficient noise-exposed adults Shemesh et al. 1993. Hearing loss itself is now established as one of the largest modifiable risk factors for dementia, so the second-order longevity stake compounds.

2i. payoff

For the deficient patient, the payoff is concrete: tinnitus severity scores improved in B₁₂-deficient patients after 6 weekly IM injections (Singh 2016 pilot, n=20 treated). Neurological symptoms (paresthesias, fatigue, brain fog, gait issues) commonly improve within weeks. For the replete adult eating a fortified Western diet, the marginal hearing payoff of additional B-vitamins is small to zero — the Durga effect was 0.7 dB over 3 years in a homocysteine-elevated, non-fortified population. For the at-risk-but-asymptomatic adult (vegan, metformin user, ≥60 with atrophic gastritis), the payoff is preventive: stable B₁₂/folate keeps homocysteine in a range that is not actively damaging the cochlear microvasculature.

2j. out-of-scope

The article should signpost related but separable topics: noise-induced hearing loss prevention, presbycusis broadly, dementia-hearing-loss link, B₁₂ and cognition more generally, and other inner-ear nutrition (magnesium for NIHL, vitamin D, omega-3s). Each has its own evidence base and population.

3. The credibility range

3a. Optimist case

B-vitamin status is a real, modifiable lever on cochlear health. Cross-sectional data consistently associate low folate and elevated homocysteine with worse age-related hearing thresholds across continents (Australia, Nigeria, Netherlands, US). The mechanism is biochemically plausible and supported by animal data: folate-deficient mice show accelerated cochlear hair-cell apoptosis, oxidative stress, and disrupted gap junctions. The one RCT in this space shows a statistically significant slowing of speech-frequency decline. Tinnitus pilot trials show a clean signal in B₁₂-deficient patients. In high-risk groups (60+, vegans, metformin users, PPI users, pernicious anemia), the prevalence of B₁₂ deficiency is 10–50%, and the cost of correction is ~$20/year. This is exactly the profile of an entry that pays back testing and supplementation in the right subpopulation: cheap, low-risk, evidence-backed for deficient individuals, plausible benefit for borderline.

3b. Skeptic case

The cross-sectional associations are vulnerable to confounding: older adults with worse hearing are more likely to be frailer, more medicated, less nutritionally optimal — all routes by which lower B₁₂/folate could be a marker of general decline rather than its cause. The Blue Mountains study found no temporal link to incident hearing loss in longitudinal follow-up, weakening the causal story Gopinath et al. 2010. The Durga trial's effect size (0.7 dB over 3 years) is below the threshold of clinical perceptibility and was conducted under conditions (homocysteine-elevated participants, non-fortified country) that don't generalize to the US adult eating fortified breakfast cereal. Berner et al. found no association in elderly Danes Berner et al. 2000. The NHANES analysis showed B₁₂ contributed nothing once folate was accounted for in a population with adequate B₁₂ intake Kabagambe et al. 2018. The tinnitus trials are small (n=40 in Singh's pilot) and the largest sober replication (Karli 2013, n=100) failed to show significant tinnitus improvement. The animal mechanism is real but operates at deficiency severities (7-fold serum folate drop) rarely seen in modern Western adults.

3c. Author's call

The entry should land as a test-then-act recommendation, not a blanket-supplement story. The defensible claim: in adults with documented B₁₂ or folate deficiency — or in the named risk groups where deficiency prevalence is high — testing and correction has a meaningful auditory and neurological payoff, with a tiny cost and risk profile. The indefensible claim: that B₁₂/folate supplementation in already-replete adults will preserve or restore hearing. Evidence score lands at 3 (clear mechanism + observational consistency + one positive RCT, but mixed null replications and small effect sizes). Controversy at 2 (no major paradigm fight; mostly arguments about effect size and whom to test). The article voice should emphasize the population-specific framing aggressively — the audience here is older adults, vegans, and patients on long-term metformin/PPI, not the general adult population.

4. Stakeholder + incentive map

Supplement industry. B-complex supplements are a substantial OTC market; "tinnitus B12" and "ear health B-complex" branded products exist and incentivize the overclaim that B₁₂ treats tinnitus broadly. Marketing pressure pushes against the deficiency-specific framing.
Audiology / ENT clinical community. Generally measured: nutritional contributors are acknowledged but not central to standard presbycusis or tinnitus management. The American Academy of Audiology has covered the systematic-review evidence neutrally. Most ENTs will order B₁₂ for new-onset tinnitus in older patients; few will counsel folate.
Primary care / geriatrics. Strong consensus that B₁₂ deficiency is under-diagnosed in older adults and in metformin/PPI users; MHRA's 2022 guidance reflects this. Hearing is a secondary concern; cognitive and neuropathic stakes dominate the case for testing MHRA 2022.
Vegan / plant-based community. Generally aware of the B₁₂ issue; supplementation guidance is standard in mainstream vegan resources. Folate is less prominent because plant-heavy diets are typically folate-rich.
Tinnitus patient communities. High noise around "vitamins for tinnitus"; small but vocal contingent reports relief, mostly likely among those with undiagnosed deficiency. Pushes against expectation calibration.
Counter-incentive — public health. Folic-acid food fortification (mandatory in US since 1998, also Canada/Costa Rica/Chile/South Africa) has materially reduced folate deficiency in fortified populations — and likely reduced any contribution of folate status to incident hearing loss NIH ODS Folate 2024. The Durga trial's conditions don't apply to fortified populations.

5. Population variability

Effect heterogeneity is large and systematic. The association strengthens in: older adults (60+, where atrophic gastritis prevalence is high), populations without folic-acid food fortification (Netherlands during Durga, parts of Europe), vegans and strict vegetarians (B₁₂ uniquely), long-term metformin users (10–50% deficient at extended use), long-term PPI/H₂-blocker users, patients with autoimmune atrophic gastritis or prior gastrectomy, noise-exposed military and occupational populations, and possibly carriers of the MTHFR C677T polymorphism (mixed data; some studies show interaction with risk).

The association weakens or disappears in: working-age US adults eating fortified diets (NHANES showed no independent B₁₂ contribution once folate was controlled), elderly Danes in one negative study, and any population with mean B₁₂ >400 pg/mL and adequate folate. The Durga trial's exclusion of B₁₂-deficient participants (entry required B₁₂ ≥200 pmol/L) and selection for elevated homocysteine means even its positive finding doesn't directly extrapolate to either deficient or replete populations.

Sex effects are weak; men may be at slightly higher risk of homocysteine-mediated effects given baseline tHcy distributions, but the elderly female cohorts (Houston 1999) show the strongest signal, suggesting the population effect dominates over sex.

6. Knowledge gaps

The principal unknowns:

No large RCT in a folate-fortified population has tested whether B₁₂+folate supplementation slows incident hearing loss. The Durga trial is the only RCT and was run in a non-fortified country; it should be replicated.
No RCT has tested whether correcting B₁₂ deficiency in older adults with documented low-normal status and presbycusis alters the slope of decline. Existing trials select either for elevated homocysteine (Durga) or documented tinnitus + deficiency (Singh).
The clinical significance of "low-normal" B₁₂ (200–350 pg/mL) for hearing remains debated. MMA and holotranscobalamin would be the better functional markers but aren't standardly available in primary care.
Whether parenteral B₁₂ outperforms high-dose oral for hearing/tinnitus outcomes specifically is not established; absorption equivalence applies broadly but tinnitus-specific dosing studies are missing.
Whether folate's effect in Durga was via homocysteine reduction or via a separate cochlear mechanism is unresolved; the trial measured both and folate's effect persisted independently of homocysteine in some sensitivity analyses.
Mechanistic gap: most direct cochlear-toxicity evidence is from rodent models with severe folate deficiency. Translation to the modest deficiencies common in human aging is inferential.

What would change the author's call: a large multi-arm RCT in fortified populations showing either a clinically meaningful (≥3 dB) slowing of presbycusis with B-vitamin supplementation, or a clean null in deficient patients showing repletion does not help auditory thresholds even when it corrects MMA. Either result would meaningfully shift the entry's evidence score and practical scope.

Brief vs. entry coverage. The input description listed B₁₂ and folate, cochlear circulation, hearing function, tinnitus, dietary intake, and supplementation. All are covered. No silent narrowing.

Category placement. Lives in hearing rather than supplements because the action and the framing are auditory: the reader's question is "does this affect my ears?", not "should I take a vitamin?". A reverse-direction supplements-category entry could exist for B₁₂ broadly — see future links.

Hard rating calls.

Evidence at 3, not 4. One positive RCT (Durga 2007) but with a tiny clinically-marginal effect (0.7 dB over 3 y) and a non-fortified-population caveat that limits transferability. Several null replications (Berner 2000; B₁₂-not-independent in Kabagambe 2018). The cross-sectional consistency is strong, the mechanism is solid, but I can't name two large rigorous trials, which is the bar for 4–5.
Action: test, not do. The entire intervention pivots on deficiency status. Recommending blanket supplementation would overshoot the data. decide was the alternative, but the test/treat path doesn't really require a clinician judgment call beyond ordering the labs — most primary-care providers will order serum B₁₂/folate routinely if asked.
Mood at 1, not 0. B₁₂ deficiency has a real depression/anxiety association but it's small, indirect, and concentrated in the deficient subgroup. A non-zero score felt honest enough to give it a paragraph in payoff; bumping higher would have over-weighted what is really a side effect of repleting a deficiency.
Audience not scoped to 60+. Considered scoping audience.ages to ["60+"], but vegans and long-term metformin/PPI users span 18–59. Kept it open and used the article body to do the targeting.

Future-link candidates (don't exist yet, should cross-link when they do):

presbycusis — the broad age-related-hearing-loss entry; this entry is one contributor among several.
tinnitus — full entry on chronic tinnitus would be the natural parent; the B₁₂-deficient subgroup is one of several actionable handles.
metformin-long-term-monitoring — B₁₂ is one item on a longer list (kidney function, lactic acidosis risk in CKD).
ppi-long-term-risks — B₁₂, magnesium, calcium absorption, fracture risk, possibly dementia.
hearing-aids-and-cognition — the dementia–hearing-loss link mentioned in stakes deserves its own treatment.
magnesium-and-noise-induced-hearing-loss — flagged in out-of-scope; separate evidence base.

Separate-entry candidates surfaced during the write. None at standalone depth — the four bullets above are the natural homes for adjacent material, not new entries surfaced by this one.

Excluded with intent.

Vitamin B₆. Also a one-carbon-cycle cofactor and contributes to homocysteine regulation, but the hearing literature on B₆ specifically is too thin to carry weight here. Mentioning it would dilute the B₁₂+folate focus the brief named.
MTHFR C677T polymorphism. Mixed literature on whether it interacts with B-vitamin status and hearing. Including it would have opened a genotyping-and-personalized-supplementation tangent that didn't earn its space. Reviewers asking about MTHFR can see Martinez-Vega et al. 2017 in the dossier.
Sudden sensorineural hearing loss (SSNHL). One Indian case-control study (2025, Indian Journal of Otology) linked low methylcobalamin and folate to SSNHL. The entry is about chronic/progressive hearing, not acute. SSNHL belongs in its own entry given the steroid-treatment-window urgency.
Karli et al. 2013 negative tinnitus trial. Mentioned in dossier credibility-range, not cited in article — the Singh pilot already encodes the deficiency-specific framing more cleanly. Adding Karli would have crowded the misconceptions paragraph without changing the call.

Voice call on the tinnitus framing. The temptation here was to lead with tinnitus — it's the more emotionally salient hearing complaint and the supplement-marketing target. Resisted because the trial signal is narrower than the cohort signal for presbycusis. Led with the broader hearing-decline story and routed tinnitus through the deficiency-specific clause.